What is HC Wainwright's Forecast for RNAC Q1 Earnings?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Cartesian Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics' Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.22) EPS and FY2026 earnings at ($4.06) EPS.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.07). The company had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.69 million.

Separately, Needham & Company LLC dropped their price objective on shares of Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Cartesian Therapeutics Stock Up 1.1%

RNAC stock opened at $10.37 on Tuesday. Cartesian Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $41.87. The firm's 50-day simple moving average is $12.17 and its 200 day simple moving average is $16.57. The stock has a market cap of $269.14 million, a PE ratio of -0.20 and a beta of 0.51.

Institutional Trading of Cartesian Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RNAC. Charles Schwab Investment Management Inc. raised its holdings in shares of Cartesian Therapeutics by 40.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 26,803 shares of the company's stock worth $480,000 after purchasing an additional 7,755 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Cartesian Therapeutics by 63.0% in the 4th quarter. Geode Capital Management LLC now owns 221,257 shares of the company's stock worth $3,963,000 after purchasing an additional 85,557 shares in the last quarter. MetLife Investment Management LLC bought a new stake in shares of Cartesian Therapeutics in the 4th quarter worth approximately $119,000. Renaissance Technologies LLC bought a new stake in shares of Cartesian Therapeutics in the 4th quarter worth approximately $247,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Cartesian Therapeutics by 28.5% in the 4th quarter. Bank of New York Mellon Corp now owns 19,407 shares of the company's stock worth $348,000 after purchasing an additional 4,305 shares in the last quarter. 86.95% of the stock is currently owned by institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.